MCID: CRD246
MIFTS: 59

Cardiovascular System Disease

Categories: Blood diseases, Cardiovascular diseases, Immune diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Cardiovascular System Disease

MalaCards integrated aliases for Cardiovascular System Disease:

Name: Cardiovascular System Disease 11 14
Abnormality of the Cardiovascular System 28 5
Cardiovascular Disease 16 75
Disease of Subdivision of Hemolymphoid System 11
Disorder of Cardiovascular System 28
Cardiovascular Diseases 43

Classifications:



External Ids:

Disease Ontology 11 DOID:1287
ICD9CM 34 429.2
MeSH 43 D002318
NCIt 49 C2931
SNOMED-CT 68 266275004
ICD10 31 I51.6
UMLS 71 C0007222

Summaries for Cardiovascular System Disease

Disease Ontology: 11 A disease of anatomical entity which occurs in the blood, heart, blood vessels or the lymphatic system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells or lymph to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis.

MalaCards based summary: Cardiovascular System Disease, also known as abnormality of the cardiovascular system, is related to coronary heart disease 1 and heart disease. An important gene associated with Cardiovascular System Disease is KCNQ1 (Potassium Voltage-Gated Channel Subfamily Q Member 1), and among its related pathways/superpathways are Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) and Mesenchymal Stem Cells and Lineage-specific Markers. The drugs Dydrogesterone and Norethisterone have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and kidney, and related phenotypes are muscle and homeostasis/metabolism

Wikipedia: 75 Cardiovascular disease (CVD) is a class of diseases that involve the heart or blood vessels. CVD... more...

Related Diseases for Cardiovascular System Disease

Diseases in the Cardiovascular System Disease family:

Autoimmune Disease of Cardiovascular System

Diseases related to Cardiovascular System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1751)
# Related Disease Score Top Affiliating Genes
1 coronary heart disease 1 33.2 SERPINE1 INS CRP APOE APOB APOA1
2 heart disease 33.2 SERPINE1 NOS3 MIR210 KCNQ1 INS IL6
3 vascular disease 33.1 SERPINE1 NOS3 MIR145 MIR143 INS IL6
4 diabetes mellitus 32.9 SERPINE1 NOS3 MIR210 MIR145 MIR143 KCNQ1
5 type 2 diabetes mellitus 32.9 SERPINE1 NOS3 MIR210 MIR145 MIR143 MIR10A
6 heart conduction disease 32.8 MIR145 KCNQ1 INS IL6 CRP ALB
7 tangier disease 32.8 APOE APOB APOA1 ALB
8 lipoprotein quantitative trait locus 32.8 SERPINE1 NOS3 MIR210 MIR145 MIR143 KCNQ1
9 hypertension, essential 32.8 SERPINE1 NOS3 MIR210 MIR145 MIR143 KCNQ1
10 abdominal obesity-metabolic syndrome quantitative trait locus 2 32.7 SERPINE1 INS IL6 CRP APOB ADIPOQ
11 lipid metabolism disorder 32.7 SERPINE1 NOS3 INS IL6 CRP APOE
12 myocardial infarction 32.7 SERPINE1 NOS3 MIR210 MIR145 MIR143 KCNQ1
13 pericardium disease 32.7 IL6 CRP ALB ACE
14 cerebrovascular disease 32.6 MIR210 MIR145 MIR143 INS IL6 CRP
15 arteriolosclerosis 32.6 CRP APOE ALB ADIPOQ ACE
16 atherosclerosis susceptibility 32.5 SERPINE1 NOS3 INS IL6 CRP CDKN2B-AS1
17 peripheral vascular disease 32.5 SERPINE1 NOS3 INS IL6 CRP APOE
18 body mass index quantitative trait locus 11 32.5 SERPINE1 NOS3 MIR210 MIR143 MIR10A INS
19 hypercholesterolemia, familial, 1 32.5 NOS3 INS CRP APOE APOB APOA1
20 aortic aneurysm 32.4 SERPINE1 NOS3 MIR145 IL6 HIF1A-AS1 CRP
21 stroke, ischemic 32.3 SERPINE1 NOS3 INS IL6 CRP CDKN2B-AS1
22 angina pectoris 32.3 NOS3 INS IL6 CRP APOA1 ACE
23 congestive heart failure 32.3 KCNQ1 INS IL6 CDKN2B-AS1 ALB ACE
24 acute myocardial infarction 32.3 SERPINE1 NOS3 INS IL6 CRP CDKN2B-AS1
25 sleep apnea 32.3 SERPINE1 NOS3 INS IL6 CRP APOE
26 peripheral artery disease 32.3 NOS3 INS IL6 CRP CDKN2B-AS1 APOE
27 osteoporosis 32.2 SERPINE1 NOS3 MIR210 MIR145 MIR10A INS
28 arteriosclerosis 32.2 SERPINE1 MIR210 INS IL6 CRP APOE
29 dilated cardiomyopathy 32.2 NOS3 MIR10A KCNQ1 INS IL6 CRP
30 chronic kidney disease 32.2 NOS3 INS IL6 CRP APOB APOA1
31 apnea, obstructive sleep 32.1 NOS3 INS IL6 CRP APOE ALB
32 abdominal obesity-metabolic syndrome 1 32.1 SERPINE1 INS APOB ADIPOQ
33 aortic aneurysm, familial abdominal, 1 32.1 SERPINE1 NOS3 IL6 CRP CDKN2B-AS1 APOE
34 intermediate coronary syndrome 32.1 MIR145 INS IL6 CRP APOB APOA1
35 non-alcoholic fatty liver disease 32.1 SERPINE1 INS IL6 CRP APOB APOA1
36 kidney disease 32.1 SERPINE1 NOS3 INS IL6 CRP APOE
37 fatty liver disease 32.0 SERPINE1 INS IL6 CRP APOE APOB
38 pulmonary hypertension 32.0 SERPINE1 NOS3 MIR210 IL6 CRP ACE
39 hypertrophic cardiomyopathy 32.0 NOS3 KCNQ1 INS IL6 CRP ALB
40 familial hyperlipidemia 32.0 SERPINE1 INS CRP APOE APOB APOA1
41 pre-eclampsia 32.0 SERPINE1 NOS3 MIR210 INS IL6 CRP
42 arteries, anomalies of 32.0 NOS3 MIR210 MIR145 MIR143 MIR10A INS
43 heart valve disease 31.9 INS IL6 CRP ALB ACE
44 hypertriglyceridemia 1 31.9 SERPINE1 INS APOE APOB APOA1
45 hypothyroidism 31.9 SERPINE1 INS CRP APOE APOB APOA1
46 covid-19 31.9 NOS3 IL6 CRP ACE
47 hyperhomocysteinemia 31.9 SERPINE1 NOS3 CRP APOE ALB
48 nutritional deficiency disease 31.9 IL6 CRP ALB ADIPOQ
49 aortic dissection 31.8 NOS3 MIR145 MIR143 IL6 CRP ALB
50 microvascular complications of diabetes 5 31.8 SERPINE1 NOS3 INS ALB ACE

Graphical network of the top 20 diseases related to Cardiovascular System Disease:



Diseases related to Cardiovascular System Disease

Symptoms & Phenotypes for Cardiovascular System Disease

MGI Mouse Phenotypes related to Cardiovascular System Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 10.1 ADIPOQ ALB APOB APOE IL6 INS
2 homeostasis/metabolism MP:0005376 10.1 ACE ADIPOQ ALB APOA1 APOB APOE
3 renal/urinary system MP:0005367 10.09 ACE ADIPOQ ALB APOE IL6 INS
4 liver/biliary system MP:0005370 10.07 ACE ADIPOQ ALB APOA1 APOB APOE
5 neoplasm MP:0002006 10 ACE ADIPOQ ALB IL6 MIR10A MIR217
6 adipose tissue MP:0005375 9.87 ACE ADIPOQ APOE IL6 INS NOS3
7 endocrine/exocrine gland MP:0005379 9.85 ACE ADIPOQ ALB APOA1 APOE IL6
8 cardiovascular system MP:0005385 9.8 ACE ADIPOQ ALB APOA1 APOB APOE
9 immune system MP:0005387 9.4 ACE ADIPOQ ALB APOB APOE CRP

Drugs & Therapeutics for Cardiovascular System Disease

Drugs for Cardiovascular System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 818)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dydrogesterone Approved, Investigational, Withdrawn Phase 4 152-62-5 9051
2
Norethisterone Approved Phase 4 68-22-4 199472 6230
3
Glyburide Approved Phase 4 10238-21-8 3488
4
Gliclazide Approved Phase 4 21187-98-4 3475
5
Rimonabant Approved, Investigational Phase 4 168273-06-1, 158681-13-1 104850
6
Torasemide Approved Phase 4 56211-40-6 41781
7
Dimethyl fumarate Approved, Investigational Phase 4 624-49-7 637568
8
Pravastatin Approved Phase 4 81093-37-0 54687
9
Fenofibrate Approved Phase 4 49562-28-9 3339
10
Atenolol Approved Phase 4 29122-68-7 2249
11
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
12
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
13
Selenium Approved, Investigational, Vet_approved Phase 4 7783-07-5, 7782-49-2 533
14
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
15
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
16
Amlodipine Approved Phase 4 88150-42-9 2162
17
Olmesartan Approved, Investigational Phase 4 144689-63-4, 144689-24-7 158781 130881
18
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
19
Amprenavir Approved, Investigational Phase 4 161814-49-9 65016
20
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
21
Ibuprofen Approved Phase 4 15687-27-1 3672
22
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
23
Doxazosin Approved Phase 4 74191-85-8 3157
24
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
25
Medroxyprogesterone acetate Approved, Investigational Phase 4 520-85-4, 71-58-9 6279 10631
26
Hydroxychloroquine Approved Phase 4 118-42-3 3652
27
Cinacalcet Approved Phase 4 226256-56-0 156419
28
Dipyridamole Approved Phase 4 58-32-2 3108
29
Adalimumab Approved, Experimental Phase 4 331731-18-1
30
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
31
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
32
Clonidine Approved Phase 4 4205-91-8, 4205-90-7 2803 20179
33
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
34
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
35
Insulin glargine Approved Phase 4 160337-95-1 118984454
36
Insulin detemir Approved Phase 4 169148-63-4 16137271
37
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
38
Quinapril Approved, Investigational Phase 4 82586-55-8, 85441-61-8 54892
39
Manidipine Approved, Investigational Phase 4 89226-50-6 4008
40
Enfuvirtide Approved, Investigational Phase 4 159519-65-0 16130199
41
Nelfinavir Approved Phase 4 159989-64-7 64143
42
Nevirapine Approved Phase 4 129618-40-2 4463
43
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
44
Indinavir Approved Phase 4 150378-17-9 5362440
45
Didanosine Approved Phase 4 69655-05-6 50599
46
Tipranavir Approved, Investigational Phase 4 174484-41-4 65027 54682461
47
Saquinavir Approved, Investigational Phase 4 127779-20-8 60787 441243
48
Lopinavir Approved Phase 4 192725-17-0 92727
49
Morphine Approved, Investigational Phase 4 57-27-2 5288826
50
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314

Interventional clinical trials:

(show top 50) (show all 3966)
# Name Status NCT ID Phase Drugs
1 Comparison of Ultra-low-dose Oral Versus Trans-dermal Hormone Therapy on Coagulation Activation and Metabolic Risk Factors for Cardiovascular Disease Unknown status NCT02264743 Phase 4 Femoston Conti;EVOREL® CONTI
2 SGLT-2 Inhibition and Cardiovascular Disease. Metabolomics Study of Potential Factors Involved in Cardio- and Nephroprotection Unknown status NCT03919656 Phase 4 Dapagliflozin 10 mg;Placebo Oral Tablet
3 A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease Unknown status NCT00133328 Phase 4 valsartan
4 Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients Unknown status NCT00247494 Phase 4 mycophenol mofetil (MMF, Cellcept®) 500 mg BID
5 Does Administration of Vitamin D in African Americans With Hypovitaminosis D and Type 2 DM Improve Inflammatory Markers of Cardiovascular Disease? Unknown status NCT01153243 Phase 4 Ergocalciferol;Placebo pill
6 Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines Unknown status NCT02797028 Phase 4 Allopurinol
7 Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients With Type 2 Diabetes Unknown status NCT02998970 Phase 4 Empagliflozin;Placebo
8 Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin. Unknown status NCT00700856 Phase 4 add-on pioglitazone;add-on sulphonylurea
9 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
10 Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI Unknown status NCT02012140 Phase 4 ticagrelor
11 Effect of Treating Sleep Apnea With Oral Appliances in the Elderly: ORACLE Study Unknown status NCT02325089 Phase 4
12 HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study) Unknown status NCT00106886 Phase 4 Folic acid, vitamin B6 and B12 or placebo
13 A Randomized, Multicenter, Open, Parallel, Phase 4 Study to Compare the Efficacy and Safety Between High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in High ASCVD Risk Patients With Type 2 diabEtes (CREATE Study) Unknown status NCT03403556 Phase 4 Rosuvamibe;Monorova
14 Homocysteine Lowering and Atherosclerosis Reduction Trial (HART) Unknown status NCT00217178 Phase 4 Vitamins: Folic acid, B6, B12
15 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease: a Randomized Clinical Trial Unknown status NCT01155128 Phase 4
16 Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis Unknown status NCT01823185 Phase 4 clopidogrel;Ticagrelor or prasugrel
17 Randomized Clinical Study to Assess the Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias Unknown status NCT01717469 Phase 4
18 Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases. Unknown status NCT00734123 Phase 4 Simvastatin or Atorvastatin;Enalapril;Aspirin or clopidogrel;Rimonabant
19 Multicenter, Randomized Trial Designed to Evaluate the Applicability of the Guidelines of the Italian Society of Diabetology for the Prevention of Cardiovascular Diseases in Type 2 Diabetes Unknown status NCT01240070 Phase 4
20 Self-Assessment Method for Statin Side-effects Or Nocebo Unknown status NCT02668016 Phase 4 Atorvastatin
21 Clinical Study of UMOD NKCC2 Interaction on Salt-sensitivity in Hypertension Unknown status NCT03354897 Phase 4 Torasemide 5Mg Tablet
22 Levosimendan Versus Dobutamine in Cardiopatic Patients Undergoing Major Non Cardiac Surgery Unknown status NCT02012946 Phase 4 Levosimendan;Dobutamine
23 Effect of Hydroxychloroquine on Endothelial Function: a Clinical Trial Unknown status NCT04161339 Phase 4 Hydroxychloroquine;Placebo oral tablet
24 PPARGC1β And CNTN4 Genotype as a Pharmacogenetic Assay of Thrombosis and Bleeding Risks - a Cross-Over Controlled Trial of Aspirin in Individuals at Increased Cardiovascular Risk. Unknown status NCT02970604 Phase 4 Aspirin
25 Trial of Statin Holiday in Patients Receiving Maintenance Dialysis Unknown status NCT03663049 Phase 4 discontinue statin
26 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
27 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
28 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease: An Interventional and Methodological Study Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril
29 Hemocontrol's Effectiveness in a RAndomized Controlled Trial on the Reduction of Cardiovascular Long-term EventS Unknown status NCT01515878 Phase 4
30 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
31 Normal Oxygenation Maintenance in Intensive Care Unit: Randomized Controlled Trial Unknown status NCT01319643 Phase 4 Oxygen
32 Effectiveness and Safety of Low-dose vs. High-dose Rosuvastatin on Long-term Cardiovascular Events in Korean Patients After Percutaneous Coronary Intervention: 30-month, Prospective, Single-center, Randomized Trial Unknown status NCT02859480 Phase 4 Rosuvastatin 5mg;Rosuvastatin 20mg
33 Randomized, Double-blind, Cross-over Placebo-controlled Study to Assess the Functional Meat Products With n-3 and Rosemary Extract Fluid in Biochemical Markers of Cardiovascular Disease Related Risk in Subjects at Low Risk for Cardiovascular Disease Completed NCT01999088 Phase 4
34 A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors Completed NCT02019264 Phase 4 Lorcaserin hydrochloride;Placebo
35 Impact of Liraglutide 3.0 on Body Fat Distribution, Visceral Adiposity, and Cardiometabolic Risk Markers In Overweight and Obese Adults at High Risk for Cardiovascular Disease Completed NCT03038620 Phase 4 Liraglutide;Placebo
36 Effect of Omega-3 Supplementation on Serum Level and Gene Expression of IGF-1and IGFBP-3 in Men With Cardiovascular Disease. Completed NCT02092584 Phase 4
37 Effects of Punicalagin and Hydroxytyrosol Mixture on Different Inflammatory Markers Related With Cardiovascular Disease: a Crossover Study in Healthy Middle-aged Volunteers Completed NCT02042742 Phase 4
38 Impact of the PCSK9 Inhibitor Evolocumab on the Pharmacodynamic Effects of Clopidogrel in Patients With Atherosclerotic Cardiovascular Disease and High On-Treatment Platelet Reactivity Completed NCT03096288 Phase 4 Evolocumab
39 A Randomised Placebo-controlled Trial of Metformin on Progression of Carotid Atherosclerosis in Non-diabetic Patients With Cardiovascular Disease Treated With Conventional Risk Reducing Agents Completed NCT00723307 Phase 4 Metformin;Placebo
40 A Multi-center, Randomized, Open-label, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab in Hypertension Patients With Low-Intermediate Risk for Cardiovascular Disease Completed NCT04120753 Phase 4 OLOMAX 20/5/5mg;OLOMAX 20/5/10mg;Olmesartan 20 mg/Amlodipine 5 mg
41 Multicentric Cross-over Trial to Assess the Glycemic Profiles on 8 Weeks of Vildagliptin and Sitagliptin Treatment, Each, in Type-2 Diabetic Patients With a Pre-existing Cardiovascular Disease Pre-treated With Insulin, Using a PROBE-design Completed NCT01686932 Phase 4 Vildagliptin;Sitagliptin
42 VIP: Vascular Imaging Project. Prospective Randomized Study on the Effect of AUC-monitored Treatment With Steroids Combined With Either a Calcineurin Inhibitor or Mycophenolate Mofetil on the Progression of Subclinical Cardiovascular Disease in Renal Transplant Recipients. Completed NCT00169910 Phase 4 AUC monitored withdrawal of MMF or CNI
43 A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Completed NCT02475057 Phase 4 Degarelix (LHRH antagonist);LHRH agonist
44 ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I. Completed NCT00153101 Phase 4 Telmisartan;Combination of Telmisartan and Ramipril;Ramipril
45 Interventions for Cardiovascular Disease: "Real-World" Effectiveness of Combined Pharmacotherapy and Behavioural Counseling for Smoking Cessation Completed NCT01623505 Phase 4 Champix;Transdermal Nicoderm patch combined with gum or inhaler;Transdermal Nicoderm patch
46 Effects of Valsartan on the Progression of Renal and Cardiovascular Disease - Kanagawa Valsartan Trial (KVT) Completed NCT00190580 Phase 4 valsartan;Conventional antihypertensive drugs
47 Subclinical Cardiovascular Disease in Psoriatic Disease Completed NCT03228017 Phase 4 Aspirin and/or Atorvastatin
48 A Trial of Telmisartan Prevention of Cardiovascular Disease Completed NCT01075698 Phase 4 Non-ARB (standard therapy);ARB (Telmisartan)
49 Reduction of Adolescent Risk Factors for Type 2 Diabetes and Cardiovascular Disease Completed NCT00934570 Phase 4 Metformin and standard exercise;Metformin Intensive exercise
50 A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen Completed NCT00346216 Phase 4 celecoxib;Ibuprofen;Naproxen

Search NIH Clinical Center for Cardiovascular System Disease

Cochrane evidence based reviews: cardiovascular diseases

Genetic Tests for Cardiovascular System Disease

Genetic tests related to Cardiovascular System Disease:

# Genetic test Affiliating Genes
1 Disorder of Cardiovascular System 28 ACE
2 Abnormality of the Cardiovascular System 28

Anatomical Context for Cardiovascular System Disease

Organs/tissues related to Cardiovascular System Disease:

MalaCards : Heart, Endothelial, Kidney, Spinal Cord, Adipocyte, Liver, Breast

Publications for Cardiovascular System Disease

Articles related to Cardiovascular System Disease:

(show top 50) (show all 32480)
# Title Authors PMID Year
1
Intracellular delivery strategies for microRNAs and potential therapies for human cardiovascular diseases. 46
21045204 2010
2
MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. 46
20624982 2010
3
Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. 53 62
20415560 2010
4
The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? 53 62
20124546 2010
5
The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: the Caerphilly Study. 53 62
19836021 2010
6
Relationship of interleukin-6 with regional and global left-ventricular function in asymptomatic individuals without clinical cardiovascular disease: insights from the Multi-Ethnic Study of Atherosclerosis. 53 62
20064818 2010
7
Genetic polymorphisms of prostacyclin synthase gene and cardiovascular disease. 53 62
20357747 2010
8
AMP-activated protein kinase: a stress-responsive kinase with implications for cardiovascular disease. 53 62
20060780 2010
9
Association of interleukin-18 levels with global arterial function and early structural changes in men without cardiovascular disease. 53 62
20075848 2010
10
Angiotensin II type 2 receptor gene polymorphisms in cardiovascular disease. 53 62
19861351 2010
11
The angiotensin II type 2 receptor in cardiovascular disease. 53 62
19861349 2010
12
Apelin and ACE2 in cardiovascular disease. 53 62
20178040 2010
13
Riboflavin lowers blood pressure in cardiovascular disease patients homozygous for the 677C-->T polymorphism in MTHFR. 53 62
19952781 2010
14
The use of network analyses for elucidating mechanisms in cardiovascular disease. 53 62
20094647 2010
15
A new frame in thromboembolic cardiovascular disease: Adipocytokine. 53 62
18723235 2010
16
Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients. 53 62
19765773 2010
17
Genetically reduced soluble epoxide hydrolase activity and risk of stroke and other cardiovascular disease. 53 62
19940276 2010
18
Interaction between fibrinogen and IL-6 genetic variants and associations with cardiovascular disease risk in the Cardiovascular Health Study. 53 62
20059469 2010
19
Insulin therapy in type 2 diabetes: insulin analogue mix 50, a potential role in reducing postprandial hyperglycaemia and cardiovascular disease. 53 62
20001427 2010
20
Interleukin 18 and cardiovascular disease in HIV-1 infection: a partner in crime? 53 62
20216908 2010
21
The yin and yang of cholesteryl ester transfer protein in cardiovascular disease. 53 62
19948970 2009
22
Growth differentiation factor-15: a new biomarker in cardiovascular disease. 53 62
20024638 2009
23
Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. 53 62
19948972 2009
24
Lower levels of ADAMTS13 are associated with cardiovascular disease in young patients. 53 62
19439298 2009
25
BK channels in cardiovascular disease: a complex story of channel dysregulation. 53 62
19749161 2009
26
The emerging role of apelin in cardiovascular disease and health. 53 62
19829178 2009
27
Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the Better Not Pout Children! Study. 53 62
19796740 2009
28
Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study. 53 62
19821969 2009
29
MicroRNA 217 modulates endothelial cell senescence via silent information regulator 1. 46
19786632 2009
30
Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. 53 62
19622615 2009
31
Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. 53 62
19770395 2009
32
Genetic determinants of cardiovascular disease: the renin-angiotensin-aldosterone system, paraoxonases, endothelin-1, nitric oxide synthase and adrenergic receptors. 53 62
19779116 2009
33
Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. 53 62
19761988 2009
34
Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent cardiovascular disease in elderly. 53 62
19339013 2009
35
Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. 53 62
19200547 2009
36
Potential for vitamin D receptor agonists in the treatment of cardiovascular disease. 53 62
19371337 2009
37
Regulation of advanced glycation end product (AGE)-receptor (RAGE) system by PPAR-gamma agonists and its implication in cardiovascular disease. 53 62
19646657 2009
38
Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. 53 62
19574922 2009
39
P-selectin 1087G/A polymorphism is associated with neuropsychological test performance in older adults with cardiovascular disease. 53 62
19590054 2009
40
Clinical impression of brain natriuretic peptide levels in demented patients without cardiovascular disease. 53 62
19702933 2009
41
The roles of PON1 and PON2 in cardiovascular disease and innate immunity. 53 62
19474728 2009
42
Association of genetic variation in serum amyloid-A with cardiovascular disease and interactions with IL6, IL1RN, IL1beta and TNF genes in the Cardiovascular Health Study. 53 62
19729864 2009
43
Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? 53 62
19556446 2009
44
miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. 46
19578358 2009
45
Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia. 53 62
19564534 2009
46
The status of glutathione peroxidase, superoxide dismutase, vitamins A, C, E and malondialdehyde in patients with cardiovascular disease in Zahedan, Southeast Iran. 53 62
19763031 2009
47
Cardiovascular disease risk in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. 53 62
19530065 2009
48
Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. 53 62
19386311 2009
49
Vitamin D deficiency and risk for cardiovascular disease. 53 62
19593102 2009
50
Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. 53 62
19369429 2009

Variations for Cardiovascular System Disease

ClinVar genetic disease variations for Cardiovascular System Disease:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 KCNQ1 NM_000218.3(KCNQ1):c.733_734del (p.Gly245fs) DEL Pathogenic
438610 rs1554893092 GRCh37: 11:2593291-2593292
GRCh38: 11:2572061-2572062

Expression for Cardiovascular System Disease

Search GEO for disease gene expression data for Cardiovascular System Disease.

Pathways for Cardiovascular System Disease

GO Terms for Cardiovascular System Disease

Cellular components related to Cardiovascular System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 10.03 INS IL6 APOE APOB APOA1 ALB
2 high-density lipoprotein particle GO:0034364 9.85 APOE APOB APOA1
3 very-low-density lipoprotein particle GO:0034361 9.8 APOE APOB APOA1
4 intermediate-density lipoprotein particle GO:0034363 9.71 APOE APOB
5 extracellular space GO:0005615 9.68 SERPINE1 MIR210 MIR143 MIR10A INS IL6
6 endocytic vesicle lumen GO:0071682 9.63 APOA1 APOB APOE
7 chylomicron GO:0042627 9.43 APOE APOB APOA1

Biological processes related to Cardiovascular System Disease according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 10.24 KCNQ1 INS CDKN2B-AS1 APOE ACE
2 negative regulation of inflammatory response GO:0050728 10.05 MIR145 APOE APOA1 ADIPOQ
3 vasodilation GO:0042311 10.01 APOE INS NOS3
4 acute-phase response GO:0006953 10 INS IL6 CRP
5 cholesterol efflux GO:0033344 9.91 APOE APOB APOA1
6 positive regulation of blood vessel endothelial cell migration GO:0043536 9.88 NOS3 MIR210 MIR143
7 positive regulation of cholesterol efflux GO:0010875 9.88 APOE APOA1 ADIPOQ
8 positive regulation of cholesterol metabolic process GO:0090205 9.87 APOE APOA1
9 lipoprotein catabolic process GO:0042159 9.85 APOE APOB
10 positive regulation of dendritic spine maintenance GO:1902952 9.8 APOE INS
11 positive regulation of phospholipid efflux GO:1902995 9.78 APOA1 APOE
12 negative regulation of angiogenesis GO:0016525 9.76 MIR217 MIR145 MIR143 MIR10A
13 positive regulation of lipid biosynthetic process GO:0046889 9.73 INS APOE APOA1
14 lipoprotein metabolic process GO:0042157 9.62 APOA1 APOB APOE
15 aorta smooth muscle tissue morphogenesis GO:0060414 9.56 MIR145 MIR143
16 negative regulation of smooth muscle cell proliferation GO:0048662 9.43 NOS3 MIR145 MIR143 APOE
17 regulation of phenotypic switching GO:1900239 9.37 MIR145 MIR143
18 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.16 MIR145 MIR143
19 lipoprotein biosynthetic process GO:0042158 9.1 APOE APOB APOA1

Molecular functions related to Cardiovascular System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 low-density lipoprotein particle receptor binding GO:0050750 9.63 CRP APOE APOB
2 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.62 APOE APOA1
3 lipid transporter activity GO:0005319 9.56 APOE APOB APOA1
4 cholesterol transfer activity GO:0120020 9.43 APOE APOB APOA1
5 mRNA base-pairing translational repressor activity GO:1903231 9.02 MIR217 MIR210 MIR145 MIR143 MIR10A

Sources for Cardiovascular System Disease

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....